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ABSTRACT 
 
 
Malaria is a devastating disease caused by parasites of the genus Plasmodium.  
Plasmodium falciparum, which is responsible for most malaria related fatalities, 
suppresses host immune responses during heterologous coinfections or following 
vaccination.  However the mechanisms responsible for this defect are not well 
defined. The mechanism and to what extent this immunosuppression is occurring 
was investigated.  This study demonstrates that both dendritic cell and T cell 
activation are impaired following a Plasmodium infection, ultimately altering the 
adaptive T cell response to secondary infections.  T cell suppression is evident 
early on following a secondary infection and continues throughout the peak of 
parasitemia.  To address the mechanism of Plasmodium T cell suppression of 
heterologous infections, both T cell activation and expression of costimulatory 
molecules on dendritic cells were analyzed.  It was found that costimulatory 
molecules on dendritic cells were downregulated, as well as the activation 
markers CD25 and CD69 on CD8 T cells.  These data demonstrate that 
Plasmodium impairs T cell activation during heterologous infections.  These data 
provide insight into how Plasmodium may be altering immune responses to 
coinfections in malaria endemic regions and how this could potentially change 
the administration of vaccines that elicit CD8 T cell responses.                
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Section I   
Introduction 
 
 
Malaria has been one of the deadliest infectious diseases throughout history and 
continues to be a threat across the globe today.  This disease can be extremely 
debilitating, with symptoms including fever, chills, anemia, and even coma [1-4].  
Throughout most tropical and subtropical regions the parasite responsible for this 
disease, of the genus Plasmodium, continues to infect up to 500 million people 
every year resulting in approximately one million deaths [2, 4].  The most 
susceptible populations in these areas are young children under the age of five 
and pregnant women [4].  Protection against this disease only arises following 
repeated exposure to Plasmodium, and sterilizing immunity is never achieved [5, 
6]. 
 There are five species of Plasmodium that are capable of infecting 
humans.  Plasmodium ovale tends to be asymptomatic and results in a clinically 
silent infection.  Similarly, Plasmodium malariae also results in very few 
symptoms or complications.  Plasmodium vivax is the most common cause of 
acute febrile illness and in some cases results in anemia, however this infection 
is rarely lethal [4].  Plasmodium knowlesi is a zoonotic species that is specific to 
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macaques, but has been reported to infect humans in southeast Asia.  The 
deadliest by far of all Plasmodium species is Plasmodium falciparum [4]. The 
blood stage of this disease oftentimes can result in death and has been shown to 
display an ever increasing resistance to drug treatment [4].  Consequently, P. 
falciparum is the target of extensive vaccine development and novel anti-malaria 
drugs.  
The life cycle of Plasmodium species is quite complex and is one of the 
many tactics that this parasite employs to evade the immune system.  Avoiding 
the immune system and preventing clearance from the host enables the parasite 
to establish infection and continue the spread of disease.  The complex life cycle 
of Plasmodium requires two hosts: a mosquito vector and a vertebrate host 
(Figure 1).  The transmission of Plasmodium species begins with development of 
the parasite in the midgut of a female mosquito of the genus Anopheles.  When 
the mosquito takes a blood meal, it injects sporozoites with its saliva into the 
dermis of the vertebrate host [7].  The sporozoites enter circulation and traverse 
directly to the liver via an actinomysin motor, initiating the liver stage of disease 
[1, 8].  During this stage, sporozoites rapidly invade hepatocytes and begin 
differentiation and asexual replication [1].  The extent of the liver stage can last 
anywhere from 10-12 days in humans and is clinically silent [1, 4, 9].   
 As the liver stage progresses, sporozoites develop into merozoites and 
are released into the blood stream as merosomes, which are blebs of hepatocyte 
membrane filled with merozoites [1].  Merosomes function as a “Trojan horse” to  
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Figure 1.  Life cycle of Plasmodium parasite. Malaria: Evolution in vector control.  Yannis 
Michalakis & François Renaud.  Nature 462, 298-300 (19 November 2009). 
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carry the merozoites out of the liver where they eventually reach the lung and 
rupture to release the merozoites [1].  Once in the blood stream, merozoites 
infect red blood cells (RBCs) which results in the clinical disease, malaria [1, 4]. 
To infect a RBC, merozoites attach to a RBC and orient themselves into a 
position to subsequently invade it [10].  Inside the parasitized red blood cell 
(pRBC), the merozoite undergoes asexual reproduction, eventually rupturing the 
RBC and releasing dozens more merozoites into the blood stream to infect more 
RBCs [10].  This cycle of infectivity perpetuates the blood stage and can 
ultimately lead to anemia and other hallmark signs of malaria [10]. 
During the maturation of the merozoites, the parasite will begin expressing 
adherent ligands, such as P. falciparum erythrocyte membrane protein 1 
(PfEMP1), which allows it to bind to multiple ligands on the vasculature, thus 
preventing passage through the spleen [1, 10]. The spleen is a secondary 
lymphoid organ that acts as a blood filter and removes pRBCs from the 
bloodstream [11].  Consequently, expression of these adherent proteins provides 
the parasite with another means of evading the host’s immune system and 
continuing infection.  Sequestration of pRBCs can also contribute to cerebral 
malaria and complications during pregnancy, which occurs when pRBCs obstruct 
blood vessels in the brain or placenta, respectively [1].  During the blood stage of 
disease, merozoites may also differentiate into gametocytes, the sexually 
reproductive form of the parasite.  Gametocytes can be taken up by another 
mosquito during a blood meal and undergo sexual reproduction. These forms of 
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the parasite will also differentiate again into sporozoites in the mosquito, allowing 
their transmission into another vertebrate host (Figure 1) [1].                 
 Although malaria vaccine development has made significant strides 
toward a successful vaccination regimen, there still exists no licensed vaccine.  
Plasmodium falciparum poses many problems when it comes to vaccine 
development, including its polymorphic nature and antigenic variation [3, 12-16]. 
Vaccines have been targeted toward multiple stages throughout the parasite’s life 
cycle including the pre-erythrocytic stage, the erythrocytic stage, and the sexually 
reproductive stage [17-19].  In the past ten years, over 40 different vaccine 
candidates targeting these various stages of disease have undergone clinical 
trials [20].  However there has been limited success with the most advanced 
candidate being the RTS,S/AS01 (RTS,S) vaccine [21].  This vaccine targets the 
pre-erythrocytic stage, or the liver stage, of the parasite and is currently in a large 
Phase III clinical trial in Africa.  The RTS,S is comprised of pieces of the 
circumsporozoite protein fused to the hepatitis B surface antigen (HBsAg) in the 
adjuvant AS01 [17, 22]. The circumsporozoite protein is the major surface protein 
found on the sporozoite that binds to liver heparan sulfate proteoglycans [1].  
Unfortunately, the RTS,S provided only modest protection against malaria in 
young infants 6 - 12 weeks of age, which is the intention-to-treat population [21].  
The vaccine efficacy was only 30%, and the efficacy waned over time [21].  
These discouraging results only further emphasize the need for an efficacious 
malaria vaccine.   
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 Other methods of malaria elimination and drug treatment are somewhat 
effective although drug resistance has become increasingly recurrent.  There are 
several drugs available for malaria treatment, with one of the more common 
being chloroquine.  Because chloroquine-resistant strains of Plasmodium 
falciparum have become a widespread problem, the most effective treatment 
currently is artemisinin-based combination therapy (ACT).  This involves a 
combination of the drug artemisinin, or derivatives of artemisinin, and other 
antimalarial drugs [23, 24].  By using combinations of antimalarial drugs, the 
chance of the parasite developing drug resistance is much lower than using a 
single drug.  Vector control has also been implemented in many areas to control 
transmission and to limit exposure to mosquitoes.  Examples include using 
insecticide-treated bed nets as well as residual indoor insecticide spraying [23].  
Unfortunately, insecticide resistance is on the rise [23]. 
 Although malaria is not a pandemic problem, it still occurs in practically all 
tropical and subtropical regions.  The Global Malaria Eradication Programme 
(GMEP) was implemented in 1955 to prevent malaria transmission and ultimately 
eradicate the disease [23, 25].  Seventy-nine countries eliminated malaria 
between 1945 and 2010 [25]. However there has recently been a resurgence of 
malaria transmission events, with 61 countries identifying new resurgent events. 
These countries participated in the GMEP, but failed to reach complete 
elimination [25].  Multiple programs such as this one have been put into action, 
yet malaria transmission is still rampant across the globe and presents a major 
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threat to large populations, especially in sub-Saharan Africa.  These data only 
further support the need for malaria elimination and control.            
 In malaria endemic regions, there are multitudes of coinfections that can 
occur with Plasmodium [26].  Malaria itself can be an extremely morbid and 
devastating disease, however when infection occurs along with a secondary 
infection, complications ensue within the host.  Multiple studies have indicated 
that when a Plasmodium infection occurs with a secondary infection, suppression 
of the immune response to the secondary infection occurs [27-34].  It is during 
the blood stage of infection when parasitemia is high that this 
immunosuppressive activity occurs [26, 27, 29, 31-33].   
 This conundrum has been implicated with multiple types of infections, 
including both bacterial and viral infections [34].  Plasmodium has been shown to 
significantly increase susceptibility and mortality to multiple bacterial infections 
including non-typhoid Salmonella, Streptococcus pneumoniae, Haemophilus 
influenzae, Staphylococcus aureus, Acinetobacter species, E. coli, and 
Pseudomonas aeruginosa [26, 31, 32].  The mechanisms behind this increase in 
susceptibility has not been fully evaluated, although it was demonstrated that 
Plasmodium impairs resistance to non-typhoid Salmonella by disrupting 
neutrophil function [35]. 
 Plasmodium species can impair immunity to viral infections as well [30, 
32, 36-38].  Human immunodeficiency virus (HIV) is prominent throughout 
practically all of sub-Saharan Africa.  Individuals coinfected with Plasmodium and 
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HIV demonstrate higher viremia [26, 32, 39].  It has also been documented that 
Epstein-Barr virus (EBV), when combined with a Plasmodium infection, can result 
in endemic Burkitt’s lymphoma (eBL) [37].  Children coinfected with malaria and 
EBV demonstrate higher viral loads and increased susceptibility to eBL [30, 36, 
37].  Endemic Burkitt’s lymphoma is hypothesized to develop because of the loss 
of T cell control of these EBV-infected B cells.  Without the control of EBV-
infected B cells, they are more likely to undergo abnormal proliferation and 
subsequent transformation [30, 36]. 
 Furthermore, immunity generated by vaccines is impaired by malaria.  
Multiple vaccines including Salmonella typhi, tetanus toxoid, and meningococcal 
polysaccharide exhibit reduced antibody responses when vaccinated individuals 
are infected with Plasmodium [29, 33].  There is also diminished protection 
against Plasmodium infection following vaccination with the malaria vaccine 
candidate, RTS,S, in adults in malaria endemic regions compared to malaria 
naïve adults [21].  Thus malaria is somehow impairing the immunity to vaccines 
elicited to Plasmodium infected individuals, which further emphasizes the effects 
this parasite may have on heterologous immune responses.     
 In addition to Plasmodium, other pathogens are also capable of 
suppressing immune responses to coinfections.  Of these, the most prominent is 
HIV.  HIV depletes the host of its CD4 T cells and eventually eliminates T cell 
help [38].  There are several other pathogens that are immunosuppressive 
including measles virus [40-42], helminth infections [43-47], viral hepatitis [48-
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50], and herpes simplex virus (HSV) [51, 52].  Measles virus induces a 
lymphopenic environment, leading to a reduction in lymphocyte proliferation and 
ultimately suppressing the immune response to subsequent pathogens [41, 42].  
Although HIV and measles virus immunosuppression is better understood 
mechanistically, the immunosuppressive characteristics of these other pathogens 
are still unknown.                                    
 These data provide insight into a significant problem that has yet to be 
fully addressed.  There are rarely cases where an individual is infected with a 
sole pathogen, especially in malaria endemic regions where coinfections are 
quite common.  Yet, there has been limited analysis in the ramifications that one 
infection may impose on another.  Malaria immunosuppression could potentially 
have major implications on vaccines administered in malaria endemic areas.  
Determining to what extent and by what mechanism this immunosuppression is 
occurring will provide crucial information that could have a major affect on 
vaccine delivery.     
 To examine Plasmodium-induced immunosuppression, two rodent-specific 
species of Plasmodium (Plasmodium chabaudi and Plasmodium yoelii) were 
employed to demonstrate immunosuppression with various heterologous (i.e., 
bacterial – Listeria monocytogenes and viral – lymphocytic choriomeningitis virus 
(LCMV)) infections.  Immunosuppression was observed following both bacterial 
and viral coinfections. The mechanism by which this suppression occurs is 
intrinsic to the activation of dendritic cells (DCs) and the priming and activation of 
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T cells. Collectively, these data provide detailed information into the 
immunosuppressive capabilities of Plasmodium species and other infectious 
pathogens, specifically LCMV.  By examining immunosuppression in 
Plasmodium specifically, it was determined that Plasmodium imparts a 
deleterious effect on T cell activation resulting in suppression of the immune 
response to subsequent infectious pathogens.     
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Section II 
Materials and Methods 
 
 
Mice and Infections 
C57BL/6 mice were purchased from the National Cancer Institute (Frederick, 
MD).  Mice were housed at the University of Tennessee animal care facility under 
the appropriate biosafety level.  For Plasmodium infections, mice were infected 
with either 105 Plasmodium yoelii 17XNL pRBCs or 106 Plasmodium chabaudi 
chabaudi AS pRBCs.  Mice that were infected with Plasmodium species were 
infected at the indicated times with either 5 x 106 actA-deficient Listeria 
monocytogenes-OVA (Lm-OVA) CFUs or 2 x 105 LCMV-armstrong PFUs.  Mice 
that were infected with wild type Listeria monocytogenes were infected with 1 x 
104 Lm 10403s CFUs and infected at the indicated time with 2 x 105 LCMV-
armstrong PFUs. Mice that were infected with LCMV followed by L. 
monocytogenes were infected with 2 x 105 LCMV-armstrong PFUs or 2 x 106 
LCMV-clone 13 PFUs followed by 5 x 106 actA-deficient Listeria monocytogenes-
OVA CFUs at the indicated times.  LCMV-armstrong infections were performed 
intraperitoneally.  All other infections were done intravenously.  The Institute 
Animal Care and Use Committee approved all animal experiments.   
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Quantification of Ag-specific T cells  
Spleens and inguinal lymph nodes were disrupted to generate single-cell 
suspensions in Hyclone RPMI media (Thermo Fisher Scientific Inc, Waltham, 
MA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Inc., 
Lawrenceville, GA) and 3% supplementary complement.  Supplementary 
complement included HEPES (Thermo Fisher Scientific Inc, Waltham, MA), L-
Glutamine (Research Products International Corp., Mt. Prospect, IL), Pen/Strep 
(Invitrogen, Grand Island, NY), Gentamicin Sulfate (Invitrogen, Grand Island, 
NY), and 2-Mercaptoethanol (Thermo Fisher Scientific Inc, Waltham, MA).  Livers 
were perfused with cold PBS through the hepatic portal vein and made into single 
cell suspensions using 35% Percoll/HBSS.  Lungs were perfused through the left 
ventricle with cold PBS and treated with DNase/collagenase for one hour prior to 
generation of single-cell suspension.  Single suspension cells were treated with 
ammonium chloride potassium (ACK) to lyse red blood cells.  Blood was 
collected in heparinized collection natelson tubes and treated with ACK to obtain 
peripheral blood mononuclear cells (PBMCs).  Tissues were harvested as 
indicated at the number of days post infection.   
 OVA-specific, LLO-190-specific, and LCMV-specific CD8 and CD4 T cells 
were detected using intracellular cytokine staining (ICS) for IFN-γ.  Cells were 
incubated five hours with brefaldin A (Biolegend, San Diego, California) with or 
without respective antigenic peptides (CD8 = 200 nM, CD4 = 4 μM) in Hyclone 
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RPMI media supplemented as described above.  After incubation, cells were 
stained with Fc block (anti-CD16/32; clone 2.4G2) and indicated antibodies (Abs) 
resuspended in FACS buffer (1x PBS, 2% fetal calf serum, 0.02% sodium azide), 
fixed and permeabilized with BD Cytofix/Cytoperm (BD Biosciences, San Diego, 
California), stained for intracellular proteins, and washed with BD Perm/Wash 
(BD Biosciences), San Diego, California).   OVA-specific, NP396-specific, and 
GP33-specific CD8 T cells were also detected by tetramer staining.  Cells were 
incubated with tetramers and Fc block in FACS buffer for 45 minutes. Antibodies 
to cell surface markers were then added. Tetramers were generated from 
biotinylated monomers (generously provided by John Harty, University of Iowa) 
conjugated with streptavidin-APC (Invitrogen, Eugene, OR).  
 
Antibodies 
The following Abs were used from Biolegend (San Diego, California):  CD8-
PerCP/Cy5.5, CD4-PerCP/Cy5.5, CD25-PE, CD69-FITC, CD40-PE, CD80-PE, 
CD86 PE, Thy1.1-APC, and IFN-γ-FITC. 
 
Parasitemia 
Percent parasitemia was calculated by performing thin blood smears.  Blood was 
obtained by performing tail snips.  Slides were fixed with methanol for ten 
minutes and then stained using Giemsa stain (Thermo Fisher Scientific Inc, 
Waltham, MA) diluted in PBS for 30 minutes.  
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BrdU assay  
Mice were injected with 200 μL 10 mg/mL bromodeoxyuridine (BrdU) (Sigma-
Aldrich, St. Louis, MO) solution intravenously three hours prior to spleen removal.  
BrdU was put into solution with 1X sterile PBS.  The BrdU Flow Kit (BD 
Pharmingen, San Diego, California) was used for labeling BrdU+ cells.  Single-
cell suspensions were generated and cells were stained with specific fluorescent 
Abs.  Cells were then fixed with BD Cytofix/Cytoperm, washed with BD 
Perm/Wash, and incubated with BD Cytoperm Permeabilization Buffer Plus.  
Cells were then treated with DNase and incubated for one hour.  The cells were 
then stained for BrdU with fluorescent α-BrdU antibodies and incubated for 20 
minutes at room temperature.  BrdU+ cells were analyzed using flow cytometry.  
 
Caspase 3/7 assay 
Spleens were disrupted into single-cell suspension.  The Caspase-3 and -7 
Assay Kit (Invitrogen, Grand Island, NY) was used to detect apoptosis.  A 30X 
FLICA working solution was added to cells and incubated for 1 hour at 37°C and 
5% CO2.  Cells were washed with 1X wash buffer and stained with a tetramer 
followed by cell surface fluorescent antibodies.  Detection of caspase-3 and -7 
was detected using flow cytometry. 
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Adoptive transfer of OT-I TCR Transgenic CD8 T cells  
Thy 1.1+ transgenic mice were used as sources of OT-I’s.  Spleens and lymph 
nodes were removed and disrupted into a single-cell suspension.  OT-I’s were 
isolated using a CD8α+ T cell isolation kit II (Miltenyi Biotec, Cologne, Germany).  
OT-I transgenic T cells were quantified and injected intravenously at the indicated 
amount.   
 
Statistical analysis 
All statistical analyses were performed using the Prism 6.0c software.  Significant 
data were represented by the following: * p=0.05-0.01, ** p=0.01-0.001,  
*** p=0.001-0.0001, ****p<0.0001 
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Section III   
Results 
 
 
Plasmodium yoelii 17XNL suppresses T cell responses to a bacterial 
coinfection 
Previous studies have indicated that Plasmodium falciparum impairs resistance 
and increases susceptibility to multiple diseases, including both bacterial and 
viral infections [26, 27, 31, 32, 37, 38]. In one particular study, it has been 
demonstrated that P. falciparum causes neutrophil dysfunction during non-
typhoid Salmonella coinfections [35].  This bacterial infection is most commonly 
associated with malaria in several regions throughout sub-Saharan Africa [31, 
32].  Therefore the objective was to determine to what extent adaptive immunity 
to heterologous coinfections was affected following a Plasmodium infection.  The 
non-lethal strain of Plasmodium yoelii (P. yoelii 17XNL) was employed to serve 
as the Plasmodium model due to it causing an acute infection with high 
parasitemia.  C57BL/6 mice were infected with 105 P. yoelii parasitized red blood 
cells (pRBCs) at day 0.  Seven days following the P. yoelii infection, both naive 
and P. yoelii infected mice were infected with 5 x 106 actA-deficient Listeria 
monocytogenes CFUs specifically expressing the protein, ovalbumin (Lm-OVA).  
The Lm-OVA strain was an attenuated strain deficient in the actA protein, 
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preventing the bacteria from spreading from cell to cell [53].  Using this strain 
provided a means to monitor OVA-specific CD8 T cells that responded to the Lm-
OVA infection.  Parasitemia of this P. yoelii strain was also monitored in order to 
determine the magnitude of infection (Figure 2).  Parasitemia was found to peak 
at approximately day 18 post-Plasmodium infection.   
A reduction in OVA-specific CD8 T cells was evident the first two weeks 
following Lm-OVA infection (Figure 3A,B).  CD4 T cells specific for the LLO-190 
peptide were also suppressed following the Lm-OVA infection, although only 
significantly through day 14 (Figure 3C,D).  These data provided insight into how 
extensive immunosuppression was occurring, with CD8 T cells being significantly 
depleted through day 21 of the experiment (Figure 3B).  Although CD4 T cells 
were not suppressed to the degree that CD8 T cells were (7-fold and 11-fold, 
respectively), there was still a significant (p = 0.0001) reduction in their numbers 
at day 14 (Figure 3D).  Both CD8 and CD4 T cell numbers recovered by day 35, 
indicating that these immunosuppressive events occur early following the P. 
yoelii infection.  The timing of T cell recovery corresponded with parasite 
clearance, indicating that the presence of the parasite was playing a role in T cell 
suppression. 
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Figure 2.  Percent parasitemia following P. yoelii infection.  C57BL/6 mice were 
infected with 105 P. yoelii 17XNL (Py) pRBC.  Blood smears were taken starting at day 
7 and continued throughout infection.  Percent parasitemia was calculated by Giemsa 
staining blood smears and performing parasitized red blood cell counts.   
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Figure 3.    P. yoelii 17XNL induces short-term suppression of T cell responses to 
secondary L. monocytogenes infection.  C57BL/6 mice were infected with 105 P. yoelii 
17XNL (Py) pRBC.  At various times post Py infection both naïve and Py infected mice 
were infected with 5x106 actA-deficient L. monocytogenes expressing ovalbumin (Lm).  
Lm-specific T cells were analyzed one-week post Lm infection.  Representative contour 
plots showing percent of CD8 T cells (A) or CD4 T cells (C) that are IFN-γ positive 
following stimulation with indicated peptide and intracellular cytokine stain (ICS).  Number 
of OVA-specific CD8 T cells (B) and LLO190-specific CD4 T cells (D) per spleen were 
quantified at the indicated time points. Data (mean+S.E.M.) are cumulative results from at 
least three independent experiments.  LLO190-specific CD4 T cell numbers at day 21, 35, 
and 70 are from one experiment.  Data were analyzed by Student’s unpaired two-tailed t 
test. 
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P. chabaudi induces suppression of T cells responding to secondary Lm-
OVA infection 
There are multiple species and strains of Plasmodium that cause malaria.  
Therefore, it is important to understand to what degree other Plasmodium 
species suppress T cell responses to coinfections. Plasmodium chabaudi AS is a 
widely used murine Plasmodium model because it induces a chronic infection, 
which is similar to infection with P. falciparum infection in humans [54].  However 
peak parasitemia is lower than that observed in P. yoelii.  This provided another 
means to examine variable levels of parasitemia and how parasite loads could 
potentially impact the T cell response to coinfections.    
 To determine whether P. chabaudi also impaired T cell responses to a 
bacterial coinfection, C57BL/6 mice were infected with 106 P. chabaudi AS 
pRBCs on day 0.  On day 7, naïve and P. chabaudi infected mice were 
subsequently infected with 5 x 106 actA-deficient Lm-OVA CFUs.  Similar to P. 
yoelii, P. chabaudi infected mice exhibited reduced OVA-specific CD8 T cells and 
LLO-specific CD4 T cells on day 14, however this was the only time point that 
showed significant differences (Figure 4).  Although there was a significant 
decrease in T cell numbers (p=0.0040), the decrease in OVA-specific CD8 T 
cells was not as severe as the P. yoelii infection (Figure 4A).  This could 
potentially be due to P. chabaudi causing a lower level of parasitemia (data not 
shown) compared to that of P. yoelii.  By day 21, T cell numbers were still lower  
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Figure 4.    Suppression of T cells responding to secondary L. monocytogenes infection is 
observed in P. chabaudi AS infected mice.  C57BL/6 mice were infected with 106 P. chabaudi 
AS (Pc) pRBC.  At various times post Pc infection both naïve and Pc infected mice were infected 
with 5x106 actA-deficient Lm.  Lm-specific T cells were analyzed one-week post Lm infection.  OVA-
specific CD8 T cells (A) or LLO190-specific CD4 T cells (B) were determined by ICS for IFN-γ.  
Data (mean+S.D.) are from three mice per group.  Data were analyzed by Student’s unpaired two-
tailed t test.   
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in P. chabaudi infected mice, although neither OVA-specific CD8 nor LLO-
specific CD4 T cell numbers were significantly reduced (Figure 4).  As 
demonstrated previously with P. yoelii, T cell numbers returned to normal by day 
35 following the P. chabaudi infection. By examining both of these murine 
Plasmodium species, suppression of T cell responses to secondary bacterial 
infections was demonstrated to occur with various species and strains.  Thus, 
Plasmodium species were capable of imparting immunosuppressive effects on T 
cell responses to secondary infections in the first two weeks following a 
Plasmodium infection. 
 
Immunosuppression of T cell response to viral infection occurs following a 
P. yoelii infection 
While there are many bacterial infections that could accompany a Plasmodium 
infection in malaria endemic areas, there are also reports of individuals displaying 
a higher susceptibility to viral infections, including HIV and EBV, when infected 
with malaria [30, 36-38].  Thus, it was also necessary to determine whether 
suppression of the immune response to a viral infection could occur.  For this 
experiment, lymphocytic choriomeningitis virus (LCMV) was utilized to serve as a 
viral infection.  LCMV-armstrong strain induces an acute infection and is typically 
cleared from the murine host within 8 days.  On day 0, C57BL/6 mice were 
infected with P. yoelii and one week later, naive and P. yoelii infected mice were 
infected with 2 x 105 LCMV-armstrong PFUs.  Eight days after the LCMV-
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armstrong infection (day 15), LCMV-specific T cells were analyzed.  The major 
antigenic peptides are NP396, GP33, and GP276 for CD8 T cells and GP61 for 
CD4 T cells. For all three CD8 T cell responses analyzed, there was a significant 
reduction in numbers (Figure 5A,B).  Similarly, GP61-specific CD4 T cells were 
lower in P. yoelii infected mice (Figure 5C,D).  These data demonstrate that P. 
yoelii also suppresses T cell responses to viral coinfections.   
 
Immunosuppression is not attributed solely to Plasmodium species  
After demonstrating that Plasmodium could suppress the adaptive immune 
response to coinfections, it was hypothesized that other types of infection could 
exhibit immunosuppression of coinfections as well.  Chronic viral infections can 
display immunosuppressive activity and induce functional impairment and 
suppression of virus-specific CD8 T cells, specifically in LCMV-clone 13 [55].  
During persistent viral infections, immunosuppressive effects can be observed 
with altered immunodominance profiles and tissue distribution, ultimately altering 
the viral T cell response to infections [55].  Therefore, the objective was to 
determine whether immunosuppression of coinfections was attributed solely to 
Plasmodium, or whether this could occur with other infections as well.  To test 
this, LCMV was used to serve as the viral infection.  LCMV-armstrong strain and 
LCMV-clone 13 strain cause an acute and chronic infection, respectively.  These 
two strains provided a means to observe differences in immunosuppression with  
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Figure 5.    P. yoelii 17XNL suppresses T cell responses to a viral coinfection.  
C57BL/6 mice were infected with 105 P. yoelii 17XNL (Py) pRBC.  One-week after Py 
infection naïve and Py infected mice were infected with 2x105 lymphocytic 
choriomeningitis virus (LCMV) Armstrong.  LCMV-specific T cells were analyzed 8 
days post LCMV infection.  Representative contour plots showing percent of CD8 T 
cells (A) or CD4 T cells (C) that are IFN-γ positive following stimulation with indicated 
peptide and ICS.  Number of NP396-, GP33- and GP276-specific CD8 T cells (B) and 
GP61-specific CD4 T cells (D) per spleen.  Data (mean+S.E.M.) are cumulative 
results from two independent experiments.  Data were analyzed by Student’s 
unpaired two-tailed t test.  
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both an acute and chronic strain, as was seen with the Plasmodium strains 
(Figures 3, 4, and 5).   
C57BL/6 mice were infected with either 2 x 105 LCMV-armstrong PFUs or 
2 x 106 LCMV-clone 13 PFUs on day 0.  One week later, naïve and LCMV 
infected mice were infected with 5 x 106 actA-deficient Lm-OVA CFUs. It was 
determined that both strains were capable of inducing immunosuppression 
(Figure 6).  Both LCMV-armstrong and LCMV-clone 13 demonstrated a 
substantial reduction in the Lm-OVA CD8 and CD4 T cell responses at day 14.  
Several mice in both LCMV-armstrong and LCMV-clone 13 infected groups had T 
cell responses below the limit of detection at day 14, therefore statistical analyses 
were not performed on these data for this time point (Figure 6B,D).  LCMV-clone 
13 demonstrated a much more severe suppressive capacity throughout the entire 
experiment for both CD8 and CD4 T cells.  OVA-specific T cell responses in 
these mice were significantly suppressed through day 70, indicating a long-term 
suppressive effect elicited by this virus.  LCMV-armstrong suppressed the 
Listeria T cell response through day 21, but the response returned to normal by 
day 35 (Figure 6B,D).  These differences in immunosuppressive capabilities 
could be due to multiple factors that have yet to be examined.  Because LCMV-
clone 13 causes a much more systemic and chronic infection, it was expected 
that this strain would cause more T cell suppression.  These data demonstrate 
that Plasmodium was not the only pathogen capable of suppressing immune 
responses to secondary infections, but a viral infection could as well.              
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Figure 6.    Acute and chronic viral infections suppress T cell responses to secondary L. 
monocytogenes infection.  C57BL/6 mice were infected with either 2x105 LCMV Armstrong (Arm) 
or 2x106 LCMV clone 13 (cl 13).  At various times post LCMV infection naïve and LCMV infected 
mice were infected with 5x106 actA-deficient Lm-OVA CFUs.  Lm-specific T cells were analyzed 
one-week post Lm infection.  Number of OVA-specific CD8 T cells (A) and LLO190-specific CD4 T 
cells (B) per spleen at the indicated time points were determined by ICS for IFN-γ.  LOD = limit of 
detection.  Data (mean+S.E.M.) are cumulative from 2 separate experiments.  Data for CD8 T cells 
on days 35 and 70 were analyzed by one-way ANOVA followed by Tukey’s multiple comparison 
test.  Data for CD8 T cells on day 21 and data for CD4 T cells on days 21, 35, and 70 were 
analyzed by a Kruskal-Wallis test followed by Dunn’s multiple comparison test.  
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Wild type Listeria infection has little to no effect on the immune response 
to viral coinfection 
After demonstrating that a viral infection was capable of suppressing a bacterial 
immune response, immunosuppression by other types of pathogens was further 
investigated by examining whether a bacterial infection was able to alter the T  
cell response to a viral infection.  To test this, a wild type strain of Listeria 
monocytogenes (Lm 10403s) served as a bacterial infection.  This strain is more 
pathogenic than the strain used in previous experiments, as it is not deficient in 
the actA protein.  C57BL/6 mice were infected with 104 Lm 10403s CFUs on day 
0 and subsequently infected with LCMV-armstrong on days 7 and 14.  On days 
15 and 22, NP396-, GP33-, and GP276-specific CD8 and GP61-specific CD4 T 
cell responses were analyzed.  At days 15 and 22, CD8 T cell responses were 
not altered in mice (Figure 7C,E).  It was shown that, on day 15, CD4 T cell 
responses were slightly less than that of LCMV only infected, but there was no 
difference by day 22 (Figure 7D,F).  Thus, a virulent Listeria infection had little 
impact on T cell responses to a viral coinfection.  Therefore, suppression of T cell 
responses to coinfections is not a universal observation for all pathogens. 
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Figure 7.    Virulent L. monocytogenes infection exhibits little to no impact 
on T cell responses to secondary LCMV infection.  C57BL/6 mice were 
infected with 0.5-1x104 virulent L. monocytogenes (strain 10403s) (Lm).  At 
various times post Lm infection naïve and Lm infected mice were infected with 
2x105 LCMV Armstrong.  LCMV-specific T cells were analyzed 8 days post 
LCMV infection.  Number of   NP396-, GP33- and GP276-specific CD8 T cells (A) 
and GP61-specific CD4 T cells (B) per spleen were determined by ICS for IFN-γ 
at the indicated time point.  Data (mean+S.E.M.) are cumulative results from two 
independent experiments.  Data were analyzed by Student’s unpaired two-tailed t 
test. 
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P. yoelii infection results in a loss of Listeria-specific CD8 T cells in 
multiple tissues 
In order to examine the mechanism of immunosuppression, it was important to 
determine if there was a loss of coinfection-specific T cells in other tissues  
besides the spleen.  It was critical to ensure that T cells being presented antigen 
in the spleen were not migrating to other tissues upon activation, thus 
contributing to the loss of T cell numbers in the spleen that was seen in previous 
experiments.  To address this possibility, C57BL/6 mice were infected with 105 P. 
yoelii 17XNL pRBCs on day 0.  On day 7, naive and P. yoelii infected mice were 
infected with 5 x 106 actA-deficient Lm-OVA CFUs.  One week later, the spleen, 
inguinal lymph nodes (iLN), liver, lungs, and blood were collected and OVA-
specific CD8 T cells were quantified using tetramer staining. There was a 
significant loss of T cell numbers in multiple tissues throughout the body, which 
demonstrated that T cell migration to tissues outside the spleen was not 
contributing to the impaired response (Figure 8).  These data demonstrated that 
depletion of the OVA-specific CD8 T cell response was accurately detected in the 
spleen and that migration of the T cells was not contributing to a loss in numbers 
in the spleen (Figure 8). This suggests that a loss of OVA-specific CD8 T cells in 
the spleen was not being compensated by an increase in other tissues and that a 
reduction in the T cell response was occurring throughout the body. Therefore, P. 
yoelii induces systemic suppression of Listeria-specific T cells during a 
coinfection.  
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Figure 8.  Loss of Listeria-specific CD8 T cells during Plasmodium infection 
occurs in multiple tissues.  C57BL/6 mice were infected with 105 P. yoelii 17XNL 
(Py) pRBCs at day 0.  One week later, naïve and Py infected mice were infected 
with 5x106 actA-deficient Lm-OVA.  Spleens, livers, inguinal lymph nodes (iLN), 
lungs, and blood were taken from mice and analyzed 14 days post Lm infection. 
OVA-specific CD8 T cells were quantified using tetramer staining.  Data 
(mean+S.E.M.) are cumulative from two independent experiments.  Data were 
analyzed using Student’s unpaired two-tailed t test.   
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Defect in T cell response occurs early after Lm-OVA infection 
One explanation for the observed decrease in Listeria-specific T cells in 
Plasmodium infected mice is altered kinetics of the T cell response.  To address 
this possibility Listeria-specific CD8 T cell responses were quantified at multiple 
time points.  C57BL/6 mice were infected with 105 P. yoelii 17XNL pRBCs on day  
0 and infected with 5 x 106 actA-deficient Lm-OVA CFUs one week later.  OVA-
specific CD8 T cells were quantified daily day 4 through day 10 post Lm-OVA 
infection.  Suppression of OVA-specific CD8 T cells occurred as early as day 4 
following the Lm-OVA infection and lasted through day 7 (Figure 9).  The early 
decrease in OVA-specific CD8 T cells in P. yoelii infected mice suggests there is 
a defect in the early stages of T cell priming that causes the decrease of Listeria-
specific T cells in P. yoelii infected mice. 
 
Loss of CD8 T cells is not due to decrease in proliferation  
The decrease in Listeria-specific T cells in P. yoelii infected mice is likely 
attributed to either a decrease in proliferation or increased apoptosis. To examine 
the proliferative potential of OVA-specific CD8 T cells in P. yoelii + Lm-OVA 
infected mice, C57BL/6 mice were infected with 105 P. yoelii 17XNL pRBCs on 
day 0 and one week later infected with 5 x 106 actA-deficient Lm-OVA CFUs.  
Beginning at day 4 post-Lm-OVA infection and continuing through day 9, mice 
were injected with 10 mg/mL bromodeoxyuridine (BrdU).  BrdU is a thymidine 
analog that is incorporated into the DNA of dividing cells and can be  
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Figure 9.    Suppression of T cells occurs early following Listeria infection.  
C57BL/6 mice were infected with 105 P. yoelii 17XNL pRBCs at day 0.  On day 7, 
naïve mice and Py infected mice were infected with 5x106 actA-deficient Lm-
OVA. (A) OVA-specific CD8 T cells were detected starting at day 4 post Lm 
infection.  OVA-specific CD8 T cells were quantified using tetramer staining.  
Data (Mean+S.E.M.) are cumulative results from four separate experiments.  
Data were analyzed by Student’s unpaired two-tailed t test.  
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tracked with BrdU-specific antibodies.  Three hours after injection of BrdU, 
spleens were removed for analysis of BrdU incorporation in OVA-specific CD8 T 
cells.  The data indicated there was no significant difference in proliferation in 
OVA-specific CD8 T cells early in the response (days 4 and 5) (Figure 10).  
Surprisingly, OVA-specific CD8 T cells in P. yoelii + Lm-OVA infected mice 
exhibited higher rates of BrdU incorporation on days 6 through 8 (Figure 10). 
These results demonstrate that P. yoelii does not impair Listeria-specific CD8 T 
cells through decreased proliferation.  This observation could help explain why 
there is a delay in the peak OVA-specific CD8 T cell response in P. yoelii infected 
mice as demonstrated in Figure 9.   
 
An increase in apoptosis occurs in OVA-specific CD8 T cells during a P. 
yoelii plus Lm-OVA infection  
Since there was no reduction in proliferation, this suggested differences in 
apoptosis might contribute to decreased T cell responses in P. yoelii infected 
mice.  To determine if OVA-specific T cells exhibited different rates of apoptosis, 
a caspase-3/7 assay was used to monitor apoptotic cells.  This assay measures 
the activity of caspases-3 and -7, two proteins that are proteolytically cleaved and 
activated during apoptotic signaling events [56].  By measuring the activation 
levels of these two proteins, apoptotic cells can be enumerated via flow 
cytometry.  C57BL/6 mice were infected with 105 P. yoelii 17XNL pRBCs at day 0  
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Figure 10.    Suppression of CD8 T cell response is not due to a decrease in 
proliferation.  C57Bl/6 mice were infected with 105 P. yoelii 17XNL pRBCs at day 0.  On 
day 7, naïve mice and Py infected mice were infected with 5x106 actA-deficient Lm-OVA.  
At days 4 – 10 post Lm infection, mice were injected with BrdU 3 hours prior to spleen 
removal to determine proliferation of OVA-specific CD8 T cells.  Data (mean+S.E.M.) are 
cumulative results from four separate experiments.  Data were analyzed by Student’s 
unpaired two-tailed t test.  
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and one week later infected with 5 x 106 actA-deficient Lm-OVA CFUs.  Starting 
at day 11, apoptosis was monitored through day 15 for detection of active 
caspase-3/7+ cells.   
 There were significant differences in apoptosis six and seven days post-
Listeria infection in P. yoelii plus Lm-OVA infected mice  (Figure 11).  On day 11, 
OVA-specific CD8 T cells in P. yoelii infected mice were undetectable.  By day 12  
there were enough cells to be able to detect caspase 3/7+ cells, although 
apoptosis only proved to be significantly higher starting at day 13 (Figure 11).  
Both days 13 and 14 were significant (p=0.0041, p=0.0002 respectively) and 
demonstrated that P. yoelii infected mice had higher levels of OVA-specific 
apoptotic cells.  By day 15, there were no differences in apoptosis.  From these 
data, it can be concluded that apoptosis may be contributing to a reduction in the 
OVA-specific T cell response following a P. yoelii infection.         
 
OT-I TCR Tg T cells behave similarly to endogenous CD8 T cell response      
Collectively, the data suggest alterations in antigen presentation and T cell 
priming likely contribute to decreased T cell responses and increased 
susceptibility to apoptosis.  To address these mechanisms requires the analysis 
of T cells early after T cell priming, which can only be accomplished through  
adoptive transfer of large numbers of T cell receptor transgenic (TCR-Tg) T cells 
specific for ovalbumin (OT-I TCR Tg T cells).  Prior to utilizing OT-I TCR Tg T 
cells, it was important to demonstrate that they behaved similar to the  
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Figure 11.  Apoptosis contributes to loss of CD8 T cell response.  C57BL/6 mice 
were infected with 105 P. yoelii 17XNL pRBCs at day 0.  On day 7, naïve mice and Py 
infected mice were infected with 5x106 actA-deficient Lm-OVA.  At days 4 – 8 post Lm 
infection, OVA-specific CD8 T cells were stained for Caspase 3/7 to determine 
apoptotic cell numbers.  Data (mean+S.E.M.) are cumulative results from two separate 
experiments.  Data were analyzed by Student’s unpaired two-tailed t test. n.d. = not 
detectable.  
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endogenous response in P. yoelii + Lm-OVA infected mice. C57BL/6 mice were 
injected with 250 OT-I TCR Tg T cells that were adoptively transferred from a 
Thy1.1+ transgenic mouse into Thy1.2+ C57BL/6 mice.  A low number adoptive 
transfer was performed in order to mimic the endogenous naïve T cell pool.  
Twenty-four hours later, mice were infected with 105 P. yoelii 17XNL pRBCs, and 
one week later, naïve and P. yoelii mice were infected with 5 x 106 actA-deficient  
Lm-OVA CFUs.  Starting at day 12, OT-I TCR Tg T cells were quantified over a 
five day span.   
Importantly, the kinetics of the OT-I TCR Tg T cell response (Figure 12) 
were comparable to the endogenous response (Figure 9).  Suppression of the Tg 
T cell response was detected as early as day 12, although T cell numbers were  
not analyzed prior to this time point.  However, P. yoelii plus Lm-OVA infected 
mice displayed similar kinetics of the T cell response to that of the endogenous 
response (Figure 9).  The peak of the P. yoelii response was delayed by 24 
hours.  These results demonstrate that OT-I TCR Tg T cells followed similar 
kinetics as seen in the endogenous response of P. yoelii + Lm-OVA infected 
mice.  Consequently, OT-I TCR Tg T cells provide a sufficient model for 
monitoring T cell priming and activation following a Lm-OVA infection. 
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Figure 12.    Adoptively transferred OT-I’s behave similarly to the endogenous 
CD8 T cell response.  Two hundred fifty OT-I’s were adoptively transferred into naïve 
C57BL/6 mice.  Half of these mice were infected with 105 P. yoelii 17XNL pRBCs one 
day later (day 0).  At day 7, naïve and Py infected mice were infected with 5x106 actA-
deficient Lm-OVA.  At days 12 – 17, OT-I cell numbers were quantified by cell surface 
staining.  Data (mean+S.E.M.) are cumulative results from two separate experiments.  
Data was analyzed by Student’s unpaired two-tailed t test.   
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Plasmodium causes impaired activation of coinfection-specific T cells 
Due to immunosuppression being observed early following a Listeria infection, it 
was imperative to investigate whether initial priming of T cells was affected in 
some way by a Plasmodium infection.  Following both TCR stimulation and  
costimulation, the cell surface markers CD69 and CD25 are upregulated and 
serve as an indicator for T cell activation [57-59].  Therefore, induction of CD69 
and CD25 were examined to determine whether P. yoelii impaired T cell 
activation events following Lm-OVA infection.  To examine these two activation 
markers, C57BL/6 mice (Thy1.2+) received ~2 x 106 adoptively transferred OT-I 
TCR Tg T cells from a Thy1.1+ TCR Tg mouse at day 0.  Mice were then infected 
with 105 P. yoelii 17XNL pRBCs later on the same day.  One week later naive 
and P. yoelii infected mice were infected with 5 x 106 actA-deficient Lm-OVA 
CFUs.  Expression of CD25 and CD69 was analyzed on days 1, 2, and 3 post 
Lm-OVA infection.  Mean fluorescence intensity was quantified to determine the 
level of expression for both CD25 (Figure 13C) and CD69 (Figure 13D).  CD25 
expression was reduced in the P. yoelii infections for three days following the Lm-
OVA infection (Figure 13C).  Similarly, the percentage of CD25+ OT-I T cells was 
also significantly lower in P. yoelii infected mice three days following Lm-OVA 
infection (Figure 13E).   
CD69 mean fluorescence intensity was significantly (p=0.0095) impaired 
one day following the Lm-OVA infection but expression in both groups of mice 
was reduced the following two days (Figure 13D). The percentage of CD69+ OT-I  
  40 
Figure 13.  Activation markers are downregulated on T cells.  At day 0, 1.5 – 1.8 x 
106 OT-I’s were adoptively transferred into naïve C57BL/6 mice. Mice were infected 
with 105 P. yoelii 17XNL pRBC and one week later infected with 5x106 actA-deficient 
Lm-OVA CFUs. On days 8, 9, and 10, OT-I cells were stained for CD25 and CD69.  
Histograms for CD25 (A) and CD69 (B) were quantified to determine CD25+ and 
CD60+ OT-I T cells.  Mean fluorescence intensity of CD25 (C) and CD69 (D) in OT-I T 
cells was quantified using flow cytometry.  Percentage of CD25+ (E) and CD69+ (F) 
OT-I T cells was also determined by fluorescent staining and flow cytometry.  Total cell 
numbers of Tg OT-I T cells were quantified by cell surface staining for Thy 1.1 (G).  
Data is representative of two separate experiments.  Data were analyzed by Student’s 
unpaired two-tailed t test.  
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T cells on day 8 was lower in P. yoelii infected mice, although this time point did 
not prove to be significant (Figure 13F).  At day 9, there were similar numbers of 
CD69+ OT-I T cells which was synonymous with reduced MFI in both groups of 
mice at the same time point (Figure 13D,F).  By day 10, the MFI and percentage  
of CD69+ OT-I T cells were both extremely low and there were no differences 
between the groups (Figure 13D,F).  From these data it can be concluded that T 
cell activation is impaired following TCR engagement as shown by the reduction 
in activation markers.   
 
Costimulatory molecules on dendritic cells in P. yoelii infected mice are not 
upregulated following Listeria infection 
There have been contradictory studies thus far on how Plasmodium species 
affect dendritic cell function and whether altered antigen presentation could be  
playing a role in suppression of T cell responses [60].  While reports have 
demonstrated that DCs are affected by malaria infection in the field [61, 62], there  
are inconsistent results from mouse models of malaria [63-69].  To address how 
dendritic cells were being affected by a P. yoelii infection, activation of dendritic 
cells was observed by investigating the level of expression of three costimulatory 
molecules: CD40, CD80, and CD86.  Full activation of T cells is dependent on 
these costimulatory molecules [70], thus this provided a means to look at DC 
function.   
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C57BL/6 mice were infected with 105 P. yoelii 17XNL pRBCs on day 0.  
One week later, both naïve and half of the P. yoelii infected mice were infected 
with 5 x 106 actA-deficient Lm-OVA CFUs.  At 24 hours post-Lm infection, DCs 
were monitored for expression of costimulatory markers.   
All three molecules were downregulated following Lm-OVA infection, with 
CD86 being the most significantly impaired.  CD86 exhibited the greatest 
decrease in expression in P. yoelii only infected mice and P. yoelii plus Lm-OVA 
infected mice (Figure 14A).  CD40 and CD80 expression were significantly 
impaired as well, though not to the extent of CD86 (Figure 14B).  These data 
suggest that Plasmodium is capable of compromising the activation of dendritic 
cells by reducing the expression of costimulatory molecules on the DC’s surface, 
thus inhibiting T cell activation as well.   
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Figure 14.  Costimulatory molecules are downregulated on dendritic cells. 
Mice were infected with 105 P. yoelii 17XNL pRBC on day 0 and one week later 
infected with 5x106 actA-deficient Lm-OVA CFUs. On day 8, dendritic cells were 
stained with CD40, CD80, and CD86 (A) and mean fluorescence intensity (MFI) 
was quantified for each costimulatory molecule (B).  Data is representative of two 
cumulative experiments.  Data were analyzed by one-way ANOVA followed by  
Tukey’s multiple comparison test.  
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Section IV 
Conclusion 
 
The host’s immunity to disease has mainly been studied in the context of tracking 
the immune response to a single infectious pathogen.  However individuals are 
often infected by more than one pathogen.  While there have been reports 
documenting suppression of immune responses following coinfections [27, 32-34, 
38, 39, 41, 50, 51, 71-73], the mechanisms and extent to which 
immunosuppression occurs remains unknown for most pathogens.  This lack of 
information presents a critical knowledge gap that needs to be addressed, 
especially in malaria endemic regions where coinfections are extremely 
prominent.  Evaluating immunosuppression and its effects will provide much 
needed information for disease treatment and vaccine delivery in these malaria 
endemic regions.   
 To address this problem, an experimental system was devised to examine 
immunosuppression in heterologous coinfections.  By utilizing multiple pathogens 
(e.g., Plasmodium, LCMV, and Listeria) the extent of immunosuppression was 
evaluated in multiple coinfections.  The results generated from these experiments 
demonstrate that immunosuppression is most severe in P. yoelii and LCMV-clone 
13 infections.  This could potentially be due to the magnitude and/or duration of 
infection with these two pathogens.  The data demonstrated that their 
suppressive effects were greater than that of P. chabaudi and LCMV-armstrong, 
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which were short-lived infections.  For example, although P. chabaudi exhibited 
immunosuppression early after infection, it did not occur to the degree of P. 
yoelii.  P. chabaudi generates a chronic infection but with much lower levels of 
parasitemia.  Parasitemia levels in the P. chabaudi only reached 7% (data not 
shown), while P. yoelii reached up to 50% pRBCs.  Likewise LCMV-armstrong 
did not display the same magnitude of immunosuppression as did LCMV-clone 
13.  LCMV-armstrong results in an acute infection that is cleared from the host 
within eight days [55].  On the contrary LCMV-clone 13 causes a chronic infection 
that can result in viremia that persist in some tissues indefinitely, which could 
perpetuate immunosuppression as shown in these data [55].   
 Whereas P. yoelii and LCMV-clone 13 demonstrated greater levels of 
immunosuppression, it appeared that wild type L. monocytogenes was not 
immunosuppressive (Figure 7).  Although this virulent strain was lethal to one-
third of the mice infected (data not shown), immunosuppression did not occur.  
These data suggest that not all infections suppress T cells responding to 
heterologous infections, however it is not known what dictates the differential 
outcome.  Importantly, the model system employed here will allow for 
mechanistic studies to determine why some infections impair T cell responses to 
subsequent infections while others do not.               
 These data may also provide information for the treatment of coinfections 
in Plasmodium-infected individuals.  Disease treatment and vaccine 
administration in Plasmodium-infected individuals comes into question if 
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immunosuppression alters the immune response to an infection.  Furthermore, if 
the immune system is incapable of mounting an appropriate response, then 
administering a vaccine could be dramatically impaired.  Indeed, there has been 
much debate on whether individuals infected with malaria should be given a 
vaccine if they are already present in the clinic [32, 34, 74].  A major problem in 
developing countries is getting people into the clinic to actually receive vaccines, 
therefore some suggest if individuals are already in the clinic then they should be 
vaccinated regardless of whether they have malaria or not [75].  This is especially 
relevant in vaccination regimens that require multiple boosters over the course of 
several months or years.  However, it is unknown if there is a correlation between 
parasite burden and impaired host immunity in humans.  Thus determining the 
mechanism and extent of immunosuppression in humans could provide valuable 
information that would determine when a vaccine should be administered to 
someone with malaria.                                  
 Previous studies have indicated that P. falciparum alters the adaptive 
immune response, increases susceptibility to heterologous infections, and 
modulates dendritic cell function [26, 28-33, 37, 39, 44, 48, 63].  However, there 
are conflicting reports about the mechanism behind immunosuppression, which 
have primarily focused on dendritic cells using malaria mouse models.  Some 
studies state that dendritic cell cytokine secretion and stimulation of T cells is 
only altered in lethal infections, while they function normally in nonlethal 
infections, such as P. yoelii 17XNL and P. chabaudi AS [65]. Leisewitz et al. 
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(2004) observed the response of the dendritic cell population to a P. chabaudi AS 
infection and demonstrated that costimulatory markers on dendritic cells are 
upregulated following infection [67].  Other research shows that Plasmodium 
induces systemic maturation of dendritic cells, thereby altering their antigen 
presentation capabilities and impairing the T cell response [66, 76].  Conversely, 
other reports have shown that P. yoelii 17XNL infections inhibit dendritic cell 
maturation and reduce the expression of costimulatory markers ([77, 78]). These 
reports are similar to the findings presented here that a nonlethal strain of P. 
yoelii does alters dendritic cell activation and proper T cell priming and 
costimulation.  However, one important caveat is our study looks at how DCs in 
Plasmodium infected mice respond during subsequent infections, which has not 
been addressed in prior studies. 
  When examining the costimulatory molecules on DCs, further evidence 
was provided that stimulation of the T cells by the DCs is also impaired.  These 
findings are similar to other studies that have shown that DC activation and T cell 
activation is compromised following a Plasmodium infection.  Urban et al. (1999) 
show that Plasmodium falciparum-infected erythrocytes affect the maturation of 
dendritic cells and that activation markers on T cells are downregulated [63].  
They also demonstrated that costimulatory molecules on DCs exposed to pRBCs 
are downregulated.  This study was the first to demonstrate that DCs could be 
affected by pRBCs.  Similarly, Millington et al. (2007) demonstrated that in a 
Plasmodium infection, DCs are capable of eliciting a normal “signal 1” to T cells, 
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or normal TCR engagement with the MHC I, but impair T cell clustering and 
priming [69].  However, this study only analyzed CD40 on DCs and did not 
examine any activation markers on the T cells themselves, therefore activation of 
the T cells was not assessed.   
 Examining costimulatory molecules on dendritic cell populations provided 
evidence that Plasmodium induced immunosuppression was not solely intrinsic 
to T cell activation, but in dendritic cell activation as well.  Expression of CD40, 
CD80, and CD86, all costimulatory molecules, were downregulated 24 hours 
following a Listeria infection (Figure 14).  Curiously, the expression of CD40 and 
CD80, but not CD86, was higher than that on DCs from naïve mice (Figure 14), 
which suggests that DCs in Plasmodium infected mice were unable to further 
upregulate expression of these costimulatory molecules following infection with 
Listeria.   
Although it has been shown that immunosuppression was induced during 
DC activation, it is not clear what the causative agent is that is inducing 
immunosuppression and altering the T cell response.  Multiple studies have 
attributed the suppressive effect of Plasmodium on DCs to hemozoin, the malaria 
pigment [64, 68, 79-84].  When a Plasmodium parasite invades a red blood cell, it 
digests hemoglobin, which in turn releases heme.  Heme is toxic to the parasite, 
thus it must convert heme into another compound, hemozoin, in order to promote 
cell survival, thus promoting its own survival. Research shows that DCs that have 
phagocytosed pRBCs containing hemozoin demonstrate immunosuppressive 
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capabilities and diminished T cell activation along with a decrease in phagocytic 
activity [64, 68].  Although that aspect was not examined in this study, hemozoin 
is likely to have some effect on antigen presenting cells that have phagocytosed 
pRBCs and may contribute to the alteration of the immune response to 
secondary infections. 
 Upon T cell priming and activation, T cells will upregulate certain activation 
markers.  CD69 is the earliest detectable activation marker following TCR 
engagement with the major histocompatibility complex (MHC).  Following TCR 
activation, CD69 is the first activation marker to be upregulated and expressed, 
typically within 3 hours of stimulation [57, 58].  Effective T cell activation also 
requires costimulation that involves the costimulatory molecules, CD80 and 
CD86, expressed on the dendritic cell.  These costimulatory molecules are 
capable of ligating receptors CD28 and CTLA-4 on the T cell, however only CD28 
ligation induces T cell activation.  In contrast, CTLA-4 ligation downregulates the 
immune response [57, 59].  CD25, another T cell activation marker, is expressed 
following induction of CD69. CD25 expression is dependent on costimulatory 
events and is only expressed following costimulation of T cells [59].  Alternatively, 
other studies have shown that this marker is dependent on “signal 3” of T cell 
priming, i.e., IL-12 stimulation [85].  Nevertheless, both of these signals occur 
downstream of TCR engagement, thus T cell activation must be compromised 
following TCR engagement as shown here by a reduction in CD25 and CD69 
expression (Figure 13).          
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 It is also possible that T cell suppression is not due to a sole contributing 
factor, but a network of components that impair T cell activation and dendritic cell 
activity.  Several studies have attributed LCMV’s suppressive capabilities to the 
secretion of IL-10, an anti-inflammatory cytokine, by immunoregulatory antigen 
presenting cells [86-89].  These studies demonstrate that dendritic cells specific 
to LCMV secrete IL-10, thus downregulating the immune response and 
perpetuating the viral infection [86-89].  Wilson et al. (2012) showed that during a 
chronic LCMV infection immunoregulatory APCs (iAPCs) are expanded and 
sustained, and they contribute to diminishing the antiviral T cell response [89].  
These iAPCs were the major source of IL-10 during persistent viral infection and 
simultaneously expressed multiple immunosuppressive molecules (PDL1, PDL2, 
and IDO), while downregulating T cell stimulatory factors, such as IL-12.  
Therefore, these cell types more than likely play a role in diminishing the antiviral 
T cell response to prevent immunopathology during a persistent infection.  On the 
contrary, an acute infection induces the expansion of immunoregulatory APCs 
but this population rapidly declines [89]. Although not examined in this study, 
these observations suggest that Plasmodium may impair coinfection-specific T 
cells through elevated production of IL-10 and immunoregulatory APCs.  Further 
investigation is needed in order to determine whether immunosuppression during 
these two types of infections are similar or are occurring via distinct regulatory 
pathways. 
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 It has been shown here that immunosuppression is not intrinsic to only 
dendritic cells, but in the activation of T cells as well.  Consequently, these 
immunosuppressive events have been deemed responsible for the reduced 
expansion of CD8 and CD4 T cells responding to a secondary infection.  This 
study has provided vital information that furthers the understanding of how 
Plasmodium impairs host immune responses during heterologous infections.       
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